Tag: Cipla

Cipla is the only Indian pharmaceutical company to join this global sustainability initiative........................

Findings from the Oncologist Survey conducted by Cipla Palliative Care and Training Centre, Pune suggest early integration of palliative care is crucial.......................

Putting into action, the recent GOI’s provision for CSR funding to support research...................

Validated and approved by ICMR, the test is found to have specificity and sensitivity of 98.09% and up to 75% respectively. This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit......................

Cipla signed a licensing agreement with MultiG for COVID-19 rapid antibody test kit..................

As part of this collaborative effort, Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA...............

Developed by Stempeutics over a period of twelve years, the breakthrough treatment designed to address the root cause of Critical Limb Ischemia at an affordable cost will be marketed and distributed in India by Cipla.....................

Cipla Limited has announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza.................

Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India.........................

Mentioned Luca Visini, Managing Director, Eli Lilly & Company India in an exclusive interaction with BioVoice where he outlined the goals of his company driven by innovation including pursual of new drug development and working towards medicines reaching people at large through different channels.....................